Transition Partners, Limited was founded in 1994 by Terry Schreier. He has accumulated two decades of varied business and strategic operating expertise, including publicly-traded healthcare, high technology, and niche-oriented growth firms. Transition Partners leverages Terry’s experience by providing senior level transitional support to firms requiring capital, management, or planning to achieve targeted corporate objectives. Representative transactions and companies with which Schreier and Transition Partners have been associated as principal or advisor are described ahead in the next section.
From 1978 to 1986, Terry served as corporate counsel for this pharmaceutical subsidiary to Hoechst Roussel, A.G. He facilitated several of Marion’s non-pharmaceutical subsidiary divestitures (14 transactions, valued at $98 million) from 1979 though 1981, spearheading a $46 million equity secondary in 1982. Schreier also provided SEC, tax, regulatory and corporate governance counsel to management of the NYSE-listed firm.
From 1983 to 1986 as COO and a Director, Terry revitalized this hospital information systems company by completing a $5 million IPO, a $3 million R&D limited partnership offering, and $11 million in leverage borrowings. He managed this NASDAQ firm’s operations from $3 million to $17 million in 3 years, becoming the 36th fastest growing financial company (Source: Financial World: August, 1986). Schreier facilitated the firm’s acquisition by TBG, Inc., a private international company for $41 million in 1986.
From 1986 to 1991 as CEO and a director, Terry coordinated all operations for this NASDAQ biopharmaceutical corporation, specializing in treatment of brain cancer. In 1987, he completed Cell’s $8 million IPO and $18 million secondary in 1989. In 1991, Schreier negotiated the successful acquisition of Air Methods Corporation by Cell after out-licensing Cell’s biotechnology products to overseas strategic healthcare partners.
From 1991 to 1994, as CEO and a Director, Terry created the strategic repositioning for this airborne medical transportation firm. By directing this companies acquisitions by Cell Technology in 1991, he led the NASDAQ firm to the fourth most-improved public company ($30 million in revenue) in the Rocky Mountain region in 1993-1994 (Source: Denver Post: April 24, 1994). Schreier completed $19 million in various public equity and warrant conversion financings for Air Methods from 1992-4.
From 1991 to 1993 as an outside director, Terry helped oversee the initiation of prototype operations for this environmental services company, including the placement of the $15 million of governmental adjustable revenue bonds through the Bank of Japan. Recontek was acquired in 1992 by PS Group, a NYSE-diversified firm controlled by Berkshire Hathaway, Inc., and Warren Buffet for $29 million.